$COCH
Envoy Medical, Inc. Stock $coch

$coch Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028894 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$59.00K	$95.00K	$316.0K
YoY Change
Cost Of Revenue	$153.0K	$234.0K	$789.0K
YoY Change	-12.57%		58.43%
Gross Profit	-$94.00K	-$139.0K	-$473.0K
YoY Change	-46.29%		-5.02%
Gross Profit Margin	-159.32%	-146.32%	-149.68%
Selling, General & Admin	$2.444M	$3.541M	$8.942M
YoY Change	39.9%		245.92%
% of Gross Profit
Research & Development	$2.360M	$3.055M	$8.956M
YoY Change	22.47%		80.02%
% of Gross Profit
Depreciation & Amortization	$34.00K	$48.00K	$133.0K
YoY Change	25.93%		77.33%
% of Gross Profit
Operating Expenses	$4.804M	$6.596M	$17.90M
YoY Change	92.73%	350.17%	266.15%
Operating Profit	-$4.898M	-$6.735M	-$18.37M
YoY Change	96.5%		275.83%
Interest Expense	-$1.110M	-$69.00K	-$69.00K
YoY Change	-132.94%	-101.57%	-100.26%
% of Operating Profit
Other Income/Expense, Net	-$1.372M	$1.923M	-$11.47M
YoY Change	-301.31%	-147.2%	2199.12%
Pretax Income	-$6.270M	-$4.881M	-$29.91M
YoY Change	-502.12%	324.69%	-244.24%
Income Tax
% Of Pretax Income
Net Earnings	-$6.270M	-$4.881M	-$29.91M
YoY Change	-973.62%	142.99%	-255.5%
Net Earnings / Revenue	-10627.12%	-5137.89%	-9464.56%
Basic Earnings Per Share	-$0.32		-$2.38
Diluted Earnings Per Share	-$0.32	-$0.25	-$2.38
COMMON SHARES
Basic Shares Outstanding	19.60M shares	19.55M shares	12.55M shares
Diluted Shares Outstanding	19.60M shares		12.55M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.945M	$4.218M	$4.218M
YoY Change	4653.89%	3813.89%	3813.89%
Cash & Equivalents	$4.945M	$4.218M
Short-Term Investments
Other Short-Term Assets	$1.109M	$957.0K	$957.0K
YoY Change	168.59%	749.53%	749.53%
Inventory	$1.455M	$1.404M	$1.404M
Prepaid Expenses
Receivables	$189.0K	$70.00K	$70.00K
Other Receivables	$32.00K	$176.0K	$176.0K
Total Short-Term Assets	$7.730M	$6.825M	$6.825M
YoY Change	1395.41%	2996.33%	2996.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$317.0K	$815.0K	$815.0K
YoY Change		146.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$750.0K	$815.0K	$815.0K
YoY Change	-98.35%	-99.81%	-99.81%
TOTAL ASSETS
Total Short-Term Assets	$7.730M	$6.825M	$6.825M
Total Long-Term Assets	$750.0K	$815.0K	$815.0K
Total Assets	$8.480M	$7.640M	$7.640M
YoY Change	-81.53%	-98.23%	-98.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$913.0K	$1.554M	$1.554M
YoY Change	-41.69%	31.97%	31.97%
Accrued Expenses	$5.621M	$4.771M	$4.771M
YoY Change	1.36%	20.92%	20.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.996M	$6.636M	$6.636M
YoY Change	-26.35%	-9.22%	-9.22%
LONG-TERM LIABILITIES
Long-Term Debt	$4.821M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.076M	$2.766M	$2.766M
YoY Change	-64.49%	-75.9%	-75.9%
Total Long-Term Liabilities	$8.897M	$2.766M	$2.766M
YoY Change	-22.49%	-75.9%	-75.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.996M	$6.636M	$6.636M
Total Long-Term Liabilities	$8.897M	$2.766M	$2.766M
Total Liabilities	$15.89M	$9.402M	$9.402M
YoY Change	-24.24%	-49.96%	-49.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$264.9M	-$257.2M
YoY Change	1277.85%	1335.84%
Common Stock	$179.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.413M	-$1.762M	-$1.762M
YoY Change
Total Liabilities & Shareholders Equity	$8.480M	$7.640M	$7.640M
YoY Change	-81.53%	-98.23%	-98.23%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.270M	-$4.881M	-$29.91M
YoY Change	-973.62%	142.99%	-255.5%
Depreciation, Depletion And Amortization	$34.00K	$48.00K	$133.0K
YoY Change	25.93%		77.33%
Cash From Operating Activities	-$5.846M	-$11.71M	-$17.65M
YoY Change	168.22%	1289.51%	564.29%
INVESTING ACTIVITIES
Capital Expenditures		$21.00K	$153.0K
YoY Change			-29.82%
Acquisitions
YoY Change
Other Investing Activities	-$109.0K
YoY Change	-100.03%
Cash From Investing Activities	-$109.0K	-$21.00K	-$153.0K
YoY Change	-100.03%	-103.24%	-113.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$109.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.683M	-891.0K	21.85M
YoY Change	-101.73%		1356.33%
NET CHANGE
Cash From Operating Activities	-$5.846M	-11.71M	-17.65M
Cash From Investing Activities	-$109.0K	-21.00K	-153.0K
Cash From Financing Activities	$6.683M	-891.0K	21.85M
Net Change In Cash	$727.0K	-12.62M	4.038M
YoY Change	-19471.17%	6397.79%	-9697.83%
FREE CASH FLOW
Cash From Operating Activities	-$5.846M	-$11.71M	-$17.65M
Capital Expenditures		$21.00K	$153.0K
Free Cash Flow	-$5.846M	-$11.73M	-$17.81M
YoY Change	161.15%		519.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40133
CY2023	dei	Entity Registrant Name EntityRegistrantName	ENVOY MEDICAL, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1369123
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4875 White Bear Parkway
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	White Bear Lake
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55110
CY2023	dei	City Area Code CityAreaCode	(877)
CY2023	dei	Local Phone Number LocalPhoneNumber	900-3277
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	44200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19599982	shares
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	Fort Lauderdale, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4218000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	70000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	176000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1295000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	957000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	129000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6825000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1648000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	351000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331000	usd
CY2023Q4	us-gaap	Assets Assets	7640000	usd
CY2022Q4	us-gaap	Assets Assets	2556000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1554000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1003000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4613000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	608000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	311000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	335000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6636000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2519000	usd
CY2023Q4	coch	Product Warranty Liability Net Of Current Portion ProductWarrantyLiabilityNetOfCurrentPortion	1923000	usd
CY2022Q4	coch	Product Warranty Liability Net Of Current Portion ProductWarrantyLiabilityNetOfCurrentPortion	2143000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	332000	usd
CY2023Q4	coch	Forward Purchase Agreement Put Option Liability Noncurrent ForwardPurchaseAgreementPutOptionLiabilityNoncurrent	103000	usd
CY2023Q4	coch	Forward Purchase Agreement Warrant Liability Noncurrent ForwardPurchaseAgreementWarrantLiabilityNoncurrent	4000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9402000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	38751000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255596000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	189904000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257242000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-225985000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-118000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-115000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-36195000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7640000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2556000	usd
CY2023	us-gaap	Revenues Revenues	316000	usd
CY2022	us-gaap	Revenues Revenues	237000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	789000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	498000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8956000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4975000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1666000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	885000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7276000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2585000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	18687000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	8943000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-18371000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8706000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-13332000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-7090000	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-69000	usd
CY2023	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability	842000	usd
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	942000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	80000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-127000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11537000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7217000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29908000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15923000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29908000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15923000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29908000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15923000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12552925	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10123169	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12552925	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10123169	shares
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-7000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29911000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15930000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-44960000	usd
CY2022	coch	Retrospective Application Of Merger RetrospectiveApplicationOfMerger	19973000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4722000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-7000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15923000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-36195000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18702000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29908000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27494000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	10982000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000000	usd
CY2023	coch	Merger Net Of Redemptions And Transaction Costs Note3 MergerNetOfRedemptionsAndTransactionCostsNote3	-1785000	usd
CY2023	coch	Meteora Forward Purchase Agreement Shares Note3 MeteoraForwardPurchaseAgreementSharesNote3	-1384000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	109000	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1349000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1575000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29908000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15923000	usd
CY2023	us-gaap	Depreciation Depreciation	133000	usd
CY2022	us-gaap	Depreciation Depreciation	75000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	1575000	usd
CY2023	coch	Change In Fair Value Of Warrant Liabilityrelated Party ChangeInFairValueOfWarrantLiabilityrelatedParty	13332000	usd
CY2022	coch	Change In Fair Value Of Warrant Liabilityrelated Party ChangeInFairValueOfWarrantLiabilityrelatedParty	7090000	usd
CY2023	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty	127000	usd
CY2022	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty	-35000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-942000	usd
CY2023	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability	842000	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	69000	usd
CY2023	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	113000	usd
CY2022	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	119000	usd
CY2023	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-99000	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-41000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-47000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	176000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	194000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	828000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	551000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	342000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-128000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-6000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-94000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	133000	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-244000	usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-520000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17654000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8805000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	153000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	218000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-153000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-218000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10000000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	109000	usd
CY2023	coch	Proceeds From The Pipe Transaction The Forward Purchase Agreement And The Business Combi ProceedsFromThePIPETransactionTheForwardPurchaseAgreementAndTheBusinessCombi	11736000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	92000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21845000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8092000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4035000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-938000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1121000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183000	usd
CY2023	coch	Deemed Capital Contribution From Related Party Upon Issuance Of Convertible Notes DeemedCapitalContributionFromRelatedPartyUponIssuanceOfConvertibleNotes	18702000	usd
CY2022	coch	Deemed Capital Contribution From Related Party Upon Issuance Of Convertible Notes DeemedCapitalContributionFromRelatedPartyUponIssuanceOfConvertibleNotes	4722000	usd
CY2023	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares	1349000	usd
CY2023	coch	Spac Excise Tax Liability Recognized Upon The Business Combination SPACExciseTaxLiabilityRecognizedUponTheBusinessCombination	2248000	usd
CY2023	coch	Convertible Debt Exchanged For Equity ConvertibleDebtExchangedForEquity	27493000	usd
CY2023	coch	Bridge Note Exchanged For Equity BridgeNoteExchangedForEquity	10982000	usd
CY2023	coch	Series A Preferred Shares Issued To Pipe Investor In Connection With The Merger SeriesAPreferredSharesIssuedToPIPEInvestorInConnectionWithTheMerger	10000000	usd
CY2023	coch	Prepaid Forward Purchase Agreement PrepaidForwardPurchaseAgreement	1384000	usd
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	425606	shares
CY2023	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	4500000	usd
CY2023	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8512	shares
CY2023Q2	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	10000000	usd
CY2023Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	257200000	usd
CY2023Q3	us-gaap	Securities Purchased Under Agreements To Resell SecuritiesPurchasedUnderAgreementsToResell	11700000	usd
CY2023Q4	us-gaap	Cash Cash	4200000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, the fair value of common stock, the fair value of convertible notes payable, the fair value of forward purchase agreement assets, the fair value of forward purchase agreement warrant liability, the fair value of warrants and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the consolidated statements of operations and comprehensive loss.</p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain items in prior financial statements have been reclassified to conform to the current presentation.</p>
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	500000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk and Significant Customers</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on accounts receivable. There were no customers that accounted for 10.0% or more of sales for the years ended December 31, 2023 and December 31, 2022, respectively. There were no customers that accounted for 10.0% or more of the accounts receivable balance as of December 31, 2023 and December 31, 2022.</p>
CY2023	coch	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2022	coch	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2023Q4	coch	Warranty Liability WarrantyLiability	2200000	usd
CY2022Q4	coch	Warranty Liability WarrantyLiability	2500000	usd
CY2023Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	300000	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	300000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	5510000	shares
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2500000	shares
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2615000	shares
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1	8512	shares
CY2023	coch	Purchase Transaction Price PurchaseTransactionPrice	10
CY2023	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	10000000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19549982	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4500000	shares
CY2023	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1162000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1010000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	158000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	164000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	121000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1295000	usd
CY2023	us-gaap	Lease Cost LeaseCost	562000	usd
CY2022	us-gaap	Lease Cost LeaseCost	690000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	127000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	124000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	127000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	124000	usd
CY2023	coch	Schedule Of Other Supplemental Information ScheduleOfOtherSupplementalInformation	Other supplemental information of lease amounts recognized in the consolidated financial statements is summarized as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	142000	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	138000	usd
CY2023	coch	Schedule Of Weighted Average Operating Lease ScheduleOfWeightedAverageOperatingLease	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average remaining lease term - in years</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.9</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> 4.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	162000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	154000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	155000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	99000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	570000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	562000	usd
CY2022Q4	us-gaap	Shares Issued SharesIssued	8695000	shares
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2478000	usd
CY2023	coch	Standard Product Warranty Reversal Of Warranty Accrual StandardProductWarrantyReversalOfWarrantyAccrual	-117000	usd
CY2023	coch	Standard Product Warranty Utilization StandardProductWarrantyUtilization	-127000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2234000	usd
CY2023Q4	us-gaap	Unrecovered Production Costs Excess Of Estimated Average Unit Cost UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost	6000	usd
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2023Q4	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.036	pure
CY2023	coch	Discount Rate DiscountRate	0.05	pure
CY2021Q1	us-gaap	Separate Account Liability Withdrawal SeparateAccountLiabilityWithdrawal	10000000	usd
CY2022Q2	us-gaap	Separate Account Liability Withdrawal SeparateAccountLiabilityWithdrawal	10000000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	59000000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	10000000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.045	pure
CY2023Q2	us-gaap	Investment Maturity Date InvestmentMaturityDate	2025-12-31
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	4000000	usd
CY2023	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.80	pure
CY2023Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	5000000	usd
CY2023Q3	us-gaap	Separate Account Liability Withdrawal SeparateAccountLiabilityWithdrawal	2000000	usd
CY2022Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1150000	shares
CY2023	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	100000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1150000	shares
CY2023Q2	coch	Gain On Warrant Liability GainOnWarrantLiability	200000	usd
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	11.5
CY2023Q4	us-gaap	Auction Market Preferred Securities Stock Series Par Value Per Share AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare	15
CY2023	us-gaap	Investment Company Issuance Of Shares Per Share InvestmentCompanyIssuanceOfSharesPerShare	10
CY2023	us-gaap	Dividends Dividends	5400000	usd
CY2023	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2023Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	10000000	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	10000000	usd
CY2023	us-gaap	Deferred Revenue Refund Payments1 DeferredRevenueRefundPayments1	2500000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	4500000	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	750000	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4000000	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1967734	shares
CY2023	coch	Expire Term For Grant ExpireTermForGrant	P10Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2085034000	shares
CY2023Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	2.4
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	720505000	shares
CY2023	coch	Percentage Of Stock Options Vested PercentageOfStockOptionsVested	0.50	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	146625000	shares
CY2023Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	2.19
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	263000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2085034	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.39
CY2023	coch	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	380300	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.6
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1967734	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.38
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	907262	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.4
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y9M18D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1449611	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2085034	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.61
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	907262	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.6
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	117300	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.66
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1060472	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.62
CY2023	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	1600000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M10D
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	156000	usd
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	63000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1356000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1575000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5776000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	645000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5776000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	645000	usd
CY2023	coch	Tax Expense At Statutory Rate TaxExpenseAtStatutoryRate	0.21	pure
CY2022	coch	Tax Expense At Statutory Rate TaxExpenseAtStatutoryRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.118	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.095	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.004	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.103	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.041	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.091	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41156000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40296000	usd
CY2023Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	3865000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1960000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2041000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-20000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	418000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	3685000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	2081000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	50228000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	44418000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50228000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44418000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	545000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	608000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	29000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	63000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	516000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	545000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5800000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	180000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	49000000	usd
CY2023Q4	coch	Deferred Tax Assets Federal Research And Development Creditss Carryforwards DeferredTaxAssetsFederalResearchAndDevelopmentCreditssCarryforwards	1800000	usd
CY2023Q4	coch	Deferred Tax Assets State Research And Development Credits Carryforwards DeferredTaxAssetsStateResearchAndDevelopmentCreditsCarryforwards	800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	500000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	600000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	600000	usd
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29908000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15923000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12552925	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10123169	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1967734	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	263000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	3913043	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14166666	shares
CY2023	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	1000000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21047443	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	263000	shares
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2500000	usd
CY2023Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2023	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	5000000	usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1700000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	coch	Forward Purchase Agreement Put Option Liability Noncurrent ForwardPurchaseAgreementPutOptionLiabilityNoncurrent		usd
CY2022Q4	coch	Forward Purchase Agreement Warrant Liability Noncurrent ForwardPurchaseAgreementWarrantLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2022	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability		usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2022	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan		usd
CY2023	coch	Exchange Of Redeemable Convertible Preferred Share For Class A Common Stock In Connection Wi ExchangeOfRedeemableConvertiblePreferredShareForClassACommonStockInConnectionWi		usd
CY2023	coch	Net Exercise Of Warrantsrelated Party Note10 NetExerciseOfWarrantsrelatedPartyNote10		usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability		usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	coch	Proceeds From The Pipe Transaction The Forward Purchase Agreement And The Business Combi ProceedsFromThePIPETransactionTheForwardPurchaseAgreementAndTheBusinessCombi		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares		usd
CY2022	coch	Spac Excise Tax Liability Recognized Upon The Business Combination SPACExciseTaxLiabilityRecognizedUponTheBusinessCombination		usd
CY2022	coch	Convertible Debt Exchanged For Equity ConvertibleDebtExchangedForEquity		usd
CY2022	coch	Bridge Note Exchanged For Equity BridgeNoteExchangedForEquity		usd
CY2022	coch	Series A Preferred Shares Issued To Pipe Investor In Connection With The Merger SeriesAPreferredSharesIssuedToPIPEInvestorInConnectionWithTheMerger		usd
CY2022	coch	Prepaid Forward Purchase Agreement PrepaidForwardPurchaseAgreement		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	coch	Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueGranted		usd
CY2023	coch	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
CY2023	coch	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense		usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense		usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions		usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations		usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15923000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29908000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10123169	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12552925	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease		shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights		shares
CY2022	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable		shares
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001840877

Files In Submission

Name	View Source	Status
0001213900-24-028894-index-headers.html	Edgar Link	pending
0001213900-24-028894-index.html	Edgar Link	pending
0001213900-24-028894.txt	Edgar Link	pending
0001213900-24-028894-xbrl.zip	Edgar Link	pending
coch-20231231.xsd	Edgar Link	pending
ea0202966-10k_envoy.htm	Edgar Link	pending
ea020296601ex10-11_envoy.htm	Edgar Link	pending
ea020296601ex10-12_envoy.htm	Edgar Link	pending
ea020296601ex10-13_envoy.htm	Edgar Link	pending
ea020296601ex10-14_envoy.htm	Edgar Link	pending
ea020296601ex10-15_envoy.htm	Edgar Link	pending
ea020296601ex19-1_envoy.htm	Edgar Link	pending
ea020296601ex31-1_envoy.htm	Edgar Link	pending
ea020296601ex31-2_envoy.htm	Edgar Link	pending
ea020296601ex32-1_envoy.htm	Edgar Link	pending
ea020296601ex32-2_envoy.htm	Edgar Link	pending
ea020296601ex4-3_envoy.htm	Edgar Link	pending
ea020296601ex97_envoy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
coch-20231231_cal.xml	Edgar Link	unprocessable
coch-20231231_def.xml	Edgar Link	unprocessable
coch-20231231_lab.xml	Edgar Link	unprocessable
coch-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0202966-10k_envoy_htm.xml	Edgar Link	completed
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCH
Envoy Medical, Inc. Stock $coch

2024 Q1 Form 10-K Financial Statement

#000121390024028894 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH Envoy Medical, Inc. Stock $coch

2024 Q1 Form 10-K Financial Statement

#000121390024028894 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH
Envoy Medical, Inc. Stock $coch